Justice Samuel Alito on Monday extended a temporary pause on a federal appeals court ruling that would have blocked nationwide access to the abortion pill mifepristone through the mail, keeping the drug available under current rules until at least Thursday at 5 p.m. EDT.
The move buys the full Supreme Court additional time to weigh emergency petitions filed by two mifepristone manufacturers, Danco Laboratories and GenBioPro, who are challenging a U.S. Court of Appeals for the 5th Circuit decision that sided with Louisiana in its lawsuit against the Food and Drug Administration.
Alito, who hears emergency matters from the 5th Circuit by default, first put the lower court ruling on hold last week. His new order does not address the merits of the case. It simply extends the status quo while the justices consider what to do next. As The Hill reported, the extension "is designed to give the justices more time to mull it over."
The dispute traces back to a 2023 FDA regulation that loosened access to mifepristone, one of two drugs used in medication abortions. Under the rule, women could obtain the pill through telehealth prescriptions, at pharmacies, and through the mail, without an in-person visit to a doctor.
Louisiana sued the FDA, arguing the agency's permissive rules violated the state's sovereignty and lacked sufficient safety data. The state called the alleged harm a "quintessential injury."
The 5th Circuit agreed. The New York Post reported that the appeals court ordered the FDA on May 1 to reinstate in-person prescribing requirements that the Biden administration had lifted in 2021. The ruling would have barred online sales and mailing of the abortion pill nationwide, a sharp reversal of the regulatory status quo.
The 5th Circuit found Louisiana was likely to succeed on the merits of its challenge, Just The News noted.
That finding mattered. It suggested the appeals court saw real legal weight behind the state's argument that the FDA had overstepped in making the drug so widely available without traditional in-person safeguards. For pro-life advocates, the 5th Circuit ruling was a significant win, one that Alito's hold has now frozen in place.
Danco Laboratories and GenBioPro rushed to the Supreme Court with emergency petitions. Both companies argued Louisiana has no right to sue because it has not suffered actual harm, and both maintained that removing the in-person requirement is safe.
Danco went further in its filing, as the Washington Examiner reported:
"The panel's ruling injects immediate confusion and upheaval into highly time-sensitive medical decisions, and it forces Danco, FDA, certified Mifeprex providers, patients, and pharmacies all to guess at what is allowed and what is not."
The Trump administration, notably, did not take a position when the battle landed at the high court. That silence is itself a data point. The administration's decision to sit out the emergency round leaves the manufacturers and Louisiana arguing directly against each other, with no signal from the executive branch about how it views the FDA's own regulation.
Alito has been one of the most active justices in pressing legal questions that matter to the conservative legal movement. His procedural intervention here, pausing a ruling that conservatives largely supported, drew reactions from both sides.
Senate Minority Leader Chuck Schumer praised the hold. Fox News reported his statement:
"It is good to see SCOTUS issue this stay to immediately restore access by mail to mifepristone."
Pro-life groups were less pleased. Kristan Hawkins, president of Students for Life, framed the stay as a delay that benefits the pharmaceutical industry at the expense of safety, telling Fox News:
"Pill pushers receive every benefit of the doubt, including today, as Justice Alito allows pill traffickers and big pharma to operate temporarily while arguments are sent to the Court."
That frustration is understandable. Pro-life advocates had watched the 5th Circuit deliver a ruling that aligned with their position, only to see it immediately frozen by a single justice's administrative order. The stay does not mean the court disagrees with the 5th Circuit. But it does mean the restrictions remain on ice while the justices take their time.
The broader context around the Court's composition adds weight to every procedural move. Alito was briefly hospitalized earlier this year after falling ill at a Federalist Society dinner, an episode that intensified speculation about potential vacancies.
At its core, the case asks whether the FDA acted within its authority when it allowed mifepristone to be distributed through pharmacies, telehealth, and the mail without requiring women to see a doctor in person. Louisiana argues the agency lacked adequate safety data and that the looser rules undermined state sovereignty. The drugmakers counter that the in-person requirement is medically unnecessary and that the state lacks standing to challenge a federal drug regulation.
The 5th Circuit sided with Louisiana on the standing question and on the merits. Whether the full Supreme Court agrees, or whether it simply lets the stay lapse and allows the restrictions to take effect, remains the central open question.
Speculation about potential Supreme Court vacancies has been a persistent theme in conservative circles, and any high-profile case Alito touches draws extra scrutiny. This one is no exception.
The AP described the practical effect of Alito's order plainly: it temporarily allows women to obtain the pill at pharmacies or through the mail, without an in-person visit to a doctor. That access continues through at least Thursday while both sides file responses.
The pause expires at 5 p.m. EDT Thursday. At that point, the Court could extend the stay again, let it lapse and allow the 5th Circuit ruling to take effect, or agree to hear the case on an expedited basis. Any of those outcomes would carry enormous political and legal consequences.
If the stay lapses, the in-person requirement snaps back into place nationwide. Telehealth prescriptions and mail delivery of mifepristone would halt. Pharmacies, providers, and patients would face immediate uncertainty about what is allowed and what is not, exactly the "confusion and upheaval" the manufacturers warned about in their filings.
If the Court takes the case, it would mark the justices' second major engagement with mifepristone access in recent terms, following the 2024 standing decision that sent an earlier challenge back without resolving the underlying regulatory questions. The recent pattern of conservative frustration with unexpected Court outcomes only raises the stakes.
Louisiana's argument, that the FDA moved too fast, with too little data, and trampled state authority in the process, is not a fringe position. It reflects a legitimate concern about an agency that used the pandemic era to permanently loosen drug-access rules that had been in place for years.
The question is whether the Supreme Court will let a lower court enforce that concern, or whether it will once again find a procedural reason to leave the regulatory status quo in place.
Thursday at 5 p.m. will tell us whether the justices are ready to answer that question, or whether they'd rather keep punting it.